Flag of the European Union EU Clinical Trials Register Help

Clinical trials for DSM III

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    87 result(s) found for: DSM III. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2013-001479-18 Sponsor Protocol Number: GENiSIS2013 Start Date*: 2014-06-09
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: A Phase III, Double Blinded, Randomised, Placebo Controlled Clinical Trial of High Dose Oral Genistein Aglycone in Patients with Sanfilippo Syndrome (Mucopolysaccharidosis III)
    Medical condition: Sanfilippo syndrome (Mucopolysaccharidosis III)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10056918 Sanfilippo's syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001265-18 Sponsor Protocol Number: LU 02-030 study No. 10403 Start Date*: 2005-04-05
    Sponsor Name:H. Lundbeck A/S
    Full Title: Protocol title No.10403: A double-blind, randomised, placebo-controlled, parallel-group, Phase III study evaluating the efficacy and safety of gaboxadol 5 mg and 10 mg daily in elderly outpatients ...
    Medical condition: Elderly outpatients with primary insomnia, diagnosed according to DSM IV -TR
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001264-45 Sponsor Protocol Number: LU 02-030 study No. 10402: Start Date*: 2005-04-06
    Sponsor Name:H. Lundbeck A/S
    Full Title: Protocol title study No. 10402: A 12-month Phase III safety study of gaboxadol 10 mg daily consisting of a 6-month double-blind, randomised, placebo-controlled, parallel-group periodfollowed by a...
    Medical condition: Elderly outpatients with primary insomnia, diagnosed according to DSM IV-TR
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000525-60 Sponsor Protocol Number: 750801.01.017 Start Date*: 2006-06-09
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Multi-center, double-blind, placebo-controlled, randomized phase III study to demonstrate the efficacy and investigate the safety of Hypericum extract WS® 5570 in patients with a Major Depressive E...
    Medical condition: Major depressive episode according to DSM-IV (single episode: 296.22, recurrent episode: 296.32; duration at least two weeks but not longer than one year).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004681-33 Sponsor Protocol Number: D1447C00001 Start Date*: 2005-04-15
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600...
    Medical condition: Bipolar Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) EE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004860-31 Sponsor Protocol Number: 2.2.20110919 Start Date*: 2011-10-27
    Sponsor Name:Medical University of Vienna
    Full Title: Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders
    Medical condition: Major Depressive Disorder Anxiety Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004775-36 Sponsor Protocol Number: DETOX-11 Start Date*: 2012-01-30
    Sponsor Name:GET SRL
    Full Title: ''A Phase III, multicenter, open-label study, to evaluate the efficacy and safety of different dosage regimens of 0.2 mg lofexidine hydrochloride (DIMATEX) in the treatment of withdrawal symptoms d...
    Medical condition: Oppiate addicts(heroin, methadone and buprenorphine)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10032707 Other specified drug dependence, continuous use LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021884-34 Sponsor Protocol Number: PERS3 Start Date*: 2013-01-24
    Sponsor Name:Radboud University Medical Centre Nijmegen
    Full Title: Relapse prevention in children and adolescents with DSM-IV Conduct Disorder treated with Risperidone: a Randomized Double blind, Placebo-Controlled, Discontinuation Study.
    Medical condition: Conduct Disorder DSM-IV-TR; 312.8x, APA 2000
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10064478 Conduct disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000567-26 Sponsor Protocol Number: 2010-021883-14 Start Date*: 2013-01-31
    Sponsor Name:Radboud University Medical Centre Nijmegen
    Full Title: A randomized double-blind, placebo-controlled study of risperidone in the treatment of DSM-IV-TR conduct disorder in children and adolescents.
    Medical condition: Conduct Disorder DSM-IV-TR; 312.8x¸ APA, 2000
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10064478 Conduct disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001490-15 Sponsor Protocol Number: RIS-BMN-3001 Start Date*: 2007-04-23
    Sponsor Name:Janssen-Cilag International N.V
    Full Title: A randomized, double-blind, placebo- and active-controlled, parallel-group study to evaluate the efficacy and safety of risperidone long-acting injectable for the prevention of mood episodes in the...
    Medical condition: Subjects with a diagnosos of bipolar I disorder who are currently experiencing a manic or mixed episode (YMRS>20 and CGI-S>/= 4 [moderate]) or who are between mood episodes (non-acute; YMRS<12 and ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10004939 Bipolar I disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-004909-16 Sponsor Protocol Number: D1447C00134 Start Date*: 2005-05-03
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600...
    Medical condition: Depressive episodes in bipolar disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004548-31 Sponsor Protocol Number: HUB-PSI-CAMAD Start Date*: 2020-04-18
    Sponsor Name:Cinto Segalàs
    Full Title: A RANDOMIZED, CONTROLLED, OPEN AND UNICENTRIC PHASE II CLINICAL TRIAL, WITH TWO PARALLEL GROUPS, TO EVALUATE THE ANTIDEPRESSANT EFFICACY OF PSYCHOTHERAPY AND CITALOPRAM IN WOMEN DIAGNOSED WITH BREA...
    Medical condition: Female patients diagnosed with breast cancer who, during the first year following the diagnosis of oncological disease, have affective symptomatology that meets DSM-V criteria for major depression.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005271-14 Sponsor Protocol Number: D1050303 Start Date*: 2013-05-06
    Sponsor Name:Sunovion Pharmaceuticals Inc
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOW-DOSE LURASIDONE IN ACUTELY PSYCHOTIC SUBJECTS WITH SCHIZOPHRENIA
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004873 10001064 Acute schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2004-000730-37 Sponsor Protocol Number: 42603ATT3002 Start Date*: 2005-02-07
    Sponsor Name:Janssen-Cilag Medical Affairs EMEA
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose-response phase III A study to evaluate safety and efficacy of Prolonged Release (PR) OROS methylphenidate (18, 36 a...
    Medical condition: Attention Deficit Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    10003731
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) CZ (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-000343-33 Sponsor Protocol Number: 248.641 Start Date*: 2009-07-29
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase III double-blind, double-dummy, placebo-controlled, 8 week fixed dose trial with pramipexole IR (Mirapex®, Mirapexin®, Pexola®, Sifrol®) 0.125 and 0.5 mg/day administered orally to investig...
    Medical condition: Tourette's Syndrome (TS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10044127 Tourette's syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001520-12 Sponsor Protocol Number: D1443C00013 Start Date*: 2008-01-11
    Sponsor Name:Unidade de Investigação em Saúde Mental e Psiquiatria do Centro Hospitalar Conde de Ferreira
    Full Title: Efficacy and distinctive effects of atypical antipsychotics on cognitive symptoms in dual diagnosis – A phase IIIb, randomized, open-labelled study to evaluate the cognitive effects of quetiapine X...
    Medical condition: Patients with both schizophrenia and substance abuse disorder
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-002857-18 Sponsor Protocol Number: H9P-MC-LNBI Start Date*: 2009-02-06
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment with LY2216684 in Adult Patients with Major Depressive Disorder
    Medical condition: Patients with Major Depressive Disorder, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision® (DSM-IV-TR; APA 2004),
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-003280-38 Sponsor Protocol Number: PSY-NIL-0006 Start Date*: 2016-05-04
    Sponsor Name:Medical University of Vienna
    Full Title: Positron Emission Tomography assessment of Ketamine Binding of the Serotonin Transporter and its Relevance for Rapid Antidepressant Response
    Medical condition: 20 patients with severe unipolar depression (structured clinical interview for DSM-IV and the 17-item Hamilton Depression Rating Scale), also 20 age and sex matched healthy controls. plus 12 HC f...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10045543 Unipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000309-60 Sponsor Protocol Number: 120101 Start Date*: 2016-03-30
    Sponsor Name:Göteborgs universitet
    Full Title: Biochemical and neuropsychological effects on Premenstrual Dysphoric Disorder after acute administration of escitalopram
    Medical condition: Premenstrual Dysphoric Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038604 - Reproductive system and breast disorders 10051537 Premenstrual dysphoric disorder PT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000512-82 Sponsor Protocol Number: OLA-D Start Date*: 2007-06-12
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Optimal Duration of Olazapine Add-on therapy in Major Depression: A double-blind, placebo-controlled, randomized, Phase III, Pilot Study in parallel group Design
    Medical condition: Major Depression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 12:30:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA